Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13965734 | 0.84 | HRH3 (0.55) | HRH3ALDH1A1MEN1TSHRKMT2A | |
| SCHEMBL15624931 | 0.84 | HRH3 (0.55) | HRH3ALDH1A1MEN1TSHRKMT2A | |
| SCHEMBL20240120 | 0.81 | ALDH1A1 (0.59) | ALDH1A1MEN1TSHRKMT2AHPGD | |
| SCHEMBL14490929 | 0.81 | ALDH1A1 (0.53) | HRH3ALDH1A1MEN1TSHRKMT2A | |
| SCHEMBL28055168 | 0.81 | HRH3 (0.77) | HRH3ALDH1A1MEN1TSHRKMT2A | |
| SCHEMBL25698055 | 0.80 | HRH3 (0.50) | HRH3ALDH1A1MEN1TSHRKMT2A | |
| SCHEMBL1764566 | 0.80 | HRH3 (0.60) | HRH3ALDH1A1MEN1TSHRKMT2A | |
| SCHEMBL310852 | 0.80 | HRH3 (0.60) | HRH3ALDH1A1MEN1TSHRKMT2A | |
| SCHEMBL11904378 | 0.80 | HPGD (0.66) | HRH3KMT2AHPGDSMN1; SMN2RECQL | |
| SCHEMBL7400389 | 0.79 | ALDH1A1 (0.66) | ALDH1A1MEN1TSHRKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10968224-B2 | 2,11-diaza-[3.3](2,6)pyridinophane compounds and their application as ligands of essential metal ion based MRI contrast agents and 52MN based PET contrast agents | DEBRECENI EGYETEM (HU) | 2021-04-06 | — | — | US | disclosed |
| US-10968224-B2 | 2,11-diaza-[3.3](2,6)pyridinophane compounds and their application as ligands of essential metal ion based MRI contrast agents and 52MN based PET contrast agents | DEBRECENI EGYETEM (HU) | 2021-04-06 | — | — | US | disclosed |
| US-10894096-B2 | 3,6,9, 15-tetraaza-bicyclo [9.3.1]pentadeca-1(14), 11(15), 12-triene based compounds and their application as ligands of essential metal ion based MRI and 52MN based PET contrast agents | DEBRECENI EGYETEM (HU) | 2021-01-19 | — | — | US | disclosed |
| US-10894096-B2 | 3,6,9, 15-tetraaza-bicyclo [9.3.1]pentadeca-1(14), 11(15), 12-triene based compounds and their application as ligands of essential metal ion based MRI and 52MN based PET contrast agents | DEBRECENI EGYETEM (HU) | 2021-01-19 | — | — | US | disclosed |
| US-20200157099-A1 | 3,6,9, 15-TETRAAZA-BICYCLO [9.3.1 ]PENTADECA- 1(14), 11(15), 12-TRIENE BASED COMPOUNDS AND THEIR APPLICATION AS LIGANDS OF ESSENTIAL METAL ION BASED MRI AND 52MN BASED PET CONTRAST AGENTS | DEBRECENI EGYETEM (HU) | 2020-05-21 | — | — | US | disclosed |
| US-20200157099-A1 | 3,6,9, 15-TETRAAZA-BICYCLO [9.3.1 ]PENTADECA- 1(14), 11(15), 12-TRIENE BASED COMPOUNDS AND THEIR APPLICATION AS LIGANDS OF ESSENTIAL METAL ION BASED MRI AND 52MN BASED PET CONTRAST AGENTS | DEBRECENI EGYETEM (HU) | 2020-05-21 | — | — | US | disclosed |
| US-10568976-B2 | 3,6,9, 15-tetraaza-bicyclo [9.3.1 ]pentadeca-1(14), 11(15), 12-triene based compounds and their application as ligands of essential metal ion based MRI and 52MN based PET contrast agents | DEBRECENI EGYETEM (HU) | 2020-02-25 | — | — | US | disclosed |
| US-10568976-B2 | 3,6,9, 15-tetraaza-bicyclo [9.3.1 ]pentadeca-1(14), 11(15), 12-triene based compounds and their application as ligands of essential metal ion based MRI and 52MN based PET contrast agents | DEBRECENI EGYETEM (HU) | 2020-02-25 | — | — | US | disclosed |
| US-20180354969-A1 | NEW 6-OXA-3,9, 15-TRIAZA-BICYCLO[9.3.1 ]PENTADEC A- 1 ( 14), 1 1 ( 15), 12-TRIENE DERIVATIVES BASED COMPOUNDS AND THEIR APPLICATION AS LIGANDS OF ESSENTIAL METAL ION BASED MRI AND 52MN BASED PET CONTRAST AGENTS | DEBRECENI EGYETEM (HU) | 2018-12-13 | — | — | US | disclosed |
| US-20180344883-A1 | NEW 3,6,9, 15-TETRAAZA-BICYCLO [9.3.1 ]PENTADECA- 1(14), 11(15), 12-TRIENE BASED COMPOUNDS AND THEIR APPLICATION AS LIGANDS OF ESSENTIAL METAL ION BASED MRI AND 52MN BASED PET CONTRAST AGENTS | DEBRECENI EGYETEM (HU) | 2018-12-06 | — | — | US | disclosed |
| US-20180282333-A1 | NEW 2, 1 L -DIAZA-[3.3](2,6)PYRIDINOPHANE COMPOUNDS AND THEIR APPLICATION AS LIGANDS OF ESSENTIAL METAL ION BASED MRI CONTRAST AGENTS AND 52MN BASED PET CONTRAST AGENTS | DEBRECENI EGYETEM (HU) | 2018-10-04 | — | — | US | disclosed |
| EP-3380472-A1 | NEW 3,6,9, 15-TETRAAZA-BICYCLO [9.3.1 ]PENTADECA- 1(14), 11(15), 12-TRIENE BASED COMPOUNDS AND THEIR APPLICATION AS LIGANDS OF ESSENTIAL METAL ION BASED MRI AND 52MN BASED PET CONTRAST AGENTS | Debreceni Egyetem (HU) | 2018-10-03 | — | — | EP | disclosed |
| EP-3380473-A1 | NEW 2, 1 L -DIAZA-[3.3](2,6)PYRIDINOPHANE COMPOUNDS AND THEIR APPLICATION AS LIGANDS OF ESSENTIAL METAL ION BASED MRI CONTRAST AGENTS AND 52MN BASED PET CONTRAST AGENTS | Debreceni Egyetem (HU) | 2018-10-03 | — | — | EP | disclosed |
| EP-3380484-A1 | NEW 6-OXA-3,9, 15-TRIAZA-BICYCLO[9.3.1 ]PENTADEC A- 1 ( 14), 1 1 ( 15), 12-TRIENE DERIVATIVES BASED COMPOUNDS AND THEIR APPLICATION AS LIGANDS OF ESSENTIAL METAL ION BASED MRI AND 52MN BASED PET CONTRAST AGENTS | Debreceni Egyetem (HU) | 2018-10-03 | — | — | EP | disclosed |
| WO-2017089847-A1 | NEW 3,6,9, 15-TETRAAZA-BICYCLO [9.3.1 ]PENTADECA- 1(14), 11(15), 12-TRIENE BASED COMPOUNDS AND THEIR APPLICATION AS LIGANDS OF ESSENTIAL METAL ION BASED MRI AND 52MN BASED PET CONTRAST AGENTS | DEBRECENI EGYETEM (HU) | 2017-06-01 | — | — | WO | disclosed |
| WO-2017089849-A1 | NEW 6-OXA-3,9, 15-TRIAZA-BICYCLO[9.3.1 ]PENTADEC A- 1 ( 14), 1 1 ( 15), 12-TRIENE DERIVATIVES BASED COMPOUNDS AND THEIR APPLICATION AS LIGANDS OF ESSENTIAL METAL ION BASED MRI AND 52MN BASED PET CONTRAST AGENTS | DEBRECENI EGYETEM (HU) | 2017-06-01 | — | — | WO | disclosed |
| WO-2017089848-A1 | NEW 2, 1 L -DIAZA-[3.3](2,6)PYRIDINOPHANE COMPOUNDS AND THEIR APPLICATION AS LIGANDS OF ESSENTIAL METAL ION BASED MRI CONTRAST AGENTS AND 52MN BASED PET CONTRAST AGENTS | DEBRECENI EGYETEM (HU) | 2017-06-01 | — | — | WO | disclosed |
| WO-2017089847-A1 | NEW 3,6,9, 15-TETRAAZA-BICYCLO [9.3.1 ]PENTADECA- 1(14), 11(15), 12-TRIENE BASED COMPOUNDS AND THEIR APPLICATION AS LIGANDS OF ESSENTIAL METAL ION BASED MRI AND 52MN BASED PET CONTRAST AGENTS | DEBRECENI EGYETEM (HU) | 2017-06-01 | — | — | WO | disclosed |
| WO-2017089848-A1 | NEW 2, 1 L -DIAZA-[3.3](2,6)PYRIDINOPHANE COMPOUNDS AND THEIR APPLICATION AS LIGANDS OF ESSENTIAL METAL ION BASED MRI CONTRAST AGENTS AND 52MN BASED PET CONTRAST AGENTS | DEBRECENI EGYETEM (HU) | 2017-06-01 | — | — | WO | disclosed |
| WO-2017089849-A1 | NEW 6-OXA-3,9, 15-TRIAZA-BICYCLO[9.3.1 ]PENTADEC A- 1 ( 14), 1 1 ( 15), 12-TRIENE DERIVATIVES BASED COMPOUNDS AND THEIR APPLICATION AS LIGANDS OF ESSENTIAL METAL ION BASED MRI AND 52MN BASED PET CONTRAST AGENTS | DEBRECENI EGYETEM (HU) | 2017-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180354969-A1 | NEW 6-OXA-3,9, 15-TRIAZA-BICYCLO[9.3.1 ]PENTADEC A- 1 ( 14), 1 1 ( 15), 12-TRIENE DERIVATIVES BASED COMPOUNDS AND THEIR APPLICATION AS LIGANDS OF ESSENTIAL METAL ION BASED MRI AND 52MN BASED PET CONTRAST AGENTS | NR4A3, SLC39A14, SLC39A3 | HRH3 323/4885ALDH1A1 2796/4885MEN1 292/4885 |
| US-20180282333-A1 | NEW 2, 1 L -DIAZA-[3.3](2,6)PYRIDINOPHANE COMPOUNDS AND THEIR APPLICATION AS LIGANDS OF ESSENTIAL METAL ION BASED MRI CONTRAST AGENTS AND 52MN BASED PET CONTRAST AGENTS | NR2E1, NR2E3, NR4A1 | HRH3 67/4885ALDH1A1 3097/4885MEN1 597/4885 |
| US-20180344883-A1 | NEW 3,6,9, 15-TETRAAZA-BICYCLO [9.3.1 ]PENTADECA- 1(14), 11(15), 12-TRIENE BASED COMPOUNDS AND THEIR APPLICATION AS LIGANDS OF ESSENTIAL METAL ION BASED MRI AND 52MN BASED PET CONTRAST AGENTS | NR4A1, NR4A3, NR0B2 | HRH3 30/4885ALDH1A1 3767/4885MEN1 376/4885 |
| US-10568976-B2 | 3,6,9, 15-tetraaza-bicyclo [9.3.1 ]pentadeca-1(14), 11(15), 12-triene based compounds and their application as ligands of essential metal ion based MRI and 52MN based PET contrast agents | SLC39A14, SLC39A11, TMEM14C | HRH3 1498/4885ALDH1A1 3109/4885MEN1 5/4885 |
| US-20200157099-A1 | 3,6,9, 15-TETRAAZA-BICYCLO [9.3.1 ]PENTADECA- 1(14), 11(15), 12-TRIENE BASED COMPOUNDS AND THEIR APPLICATION AS LIGANDS OF ESSENTIAL METAL ION BASED MRI AND 52MN BASED PET CONTRAST AGENTS | SLC39A14, SLC39A11, TMEM14C | HRH3 1498/4885ALDH1A1 3109/4885MEN1 5/4885 |
| US-10894096-B2 | 3,6,9, 15-tetraaza-bicyclo [9.3.1]pentadeca-1(14), 11(15), 12-triene based compounds and their application as ligands of essential metal ion based MRI and 52MN based PET contrast agents | SLC39A14, SLC39A11, TMEM14C | HRH3 1498/4885ALDH1A1 3109/4885MEN1 5/4885 |
| US-10968224-B2 | 2,11-diaza-[3.3](2,6)pyridinophane compounds and their application as ligands of essential metal ion based MRI contrast agents and 52MN based PET contrast agents | NR2E1, NR2E3, NCOR1 | HRH3 58/4885ALDH1A1 3260/4885MEN1 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.